Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET

Company Participants

Allison Wey - Senior Vice President of Investor Relations

Paul Edick - Chairman & Chief Executive Officer

Steven Pieper - Chief Financial Officer

John Shannon - Chief Operating Officer

Conference Call Participants

David Amsellem - Piper Sandler

Juan Luis - Blaire Partners

Operator

Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today. [Operator Instructions] I will now hand over to your host, Allison Wey, Senior Vice President of Investor Relations. Please go ahead.

Allison Wey

Thank you, Bruno. Good morning and welcome to Xeris Biopharma's third quarter financial results conference call and webcast. A press release with the company's financial results was issued earlier this morning and can be found on our website. We are joined this morning by Paul Edick, Chairman and CEO; John Shannon, our Chief Operating Officer; and Steve Pieper, our Chief Financial Officer. After our prepared remarks, we will open the lines for questions. In addition, we will be extending the Q&A portion to answer a number of questions we've been routinely receiving from some of our shareholders.

Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, prospects and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. For more information on such risks, please refer to our earnings press release and risk factors included in our SEC filings, including our quarterly report on Form 10-Q that will be filed later today. Any forward-looking statements in this call represent our views only as of the date of this call and subject to applicable laws. We disclaim any obligations to update such statements.

I'll now turn the call over to Paul.

Paul Edick

Thanks, Allison. Good morning to everybody and thank you for joining us today. I'm excited to once again say that the entire Xeris organization continues to perform at a very high level, most importantly delivering for patients and we remain focused on building a substantial patient-centric, self-sustaining biopharma enterprise. We recorded total net revenue of $48 million in the third quarter which is a 63% increase from the third quarter of 2022, making this the fourth consecutive quarter of at least 50% net revenue growth from prior year and we posted a 27% increase from the second quarter of this year.